EGFR testing and the CAP/IASLC/AMP lung cancer biomarker testing guidelines: knowledge gaps and future directions

2015 ◽  
Vol 4 (2) ◽  
pp. 87-95
Author(s):  
Elena Vigliar ◽  
Umberto Malapelle ◽  
Claudio Bellevicine ◽  
Giancarlo Troncone
Keyword(s):  
Lung Cancer ◽  
Cancer Biomarker ◽  
Knowledge Gaps ◽  
Future Directions ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

scholarly journals Lung cancer biomarker testing: perspective from Europe

2020 ◽  
Vol 9 (3) ◽  
pp. 887-897
Author(s):  
Erik Thunnissen ◽  
Birgit Weynand ◽  
Dalma Udovicic-Gagula ◽  
Luka Brcic ◽  
Malgorzata Szolkowska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Biomarker ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

scholarly journals EP1.09-17 Spanish Lung Cancer Biomarker Testing Registry (Lungpath): Descriptive Analysis Focus in ALK Traslocation Results

2019 ◽  
Vol 14 (10) ◽  
pp. S1004-S1005
Author(s):  
J. Martin Lopez ◽  
L. Aduz Alexandre ◽  
S. Gatius Caldero ◽  
A. Navarro Gonzales ◽  
P. Saiz Lopez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Descriptive Analysis ◽  
Cancer Biomarker ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

Trends in non-small cell lung cancer biomarker testing rates in the US and Western Europe from 2014-2017.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e20515-e20515 ◽  
Author(s):  
Bijal Shah-Manek ◽  
Chitra Karki ◽  
Sarah Whitmire ◽  
Long Ha ◽  
Samantha Martino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Western Europe ◽  
Cancer Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Us ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

scholarly journals Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

2021 ◽  
pp. jclinpath-2020-207280
Author(s):  
Clara Salas ◽  
Javier Martín-López ◽  
Antonio Martínez-Pozo ◽  
Teresa Hernández-Iglesias ◽  
David Carcedo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Real World ◽  
Cancer Biomarker ◽  
The Other ◽  
Molecular Testing ◽  
Sample Type ◽  
Anaplastic Lymphoma ◽  
Testing Rate ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

AimThe aim of this study was to describe the testing rate and frequency of molecular alterations observed in the Lung Cancer Biomarker Testing Registry (LungPath).MethodsA descriptive study of NSCLC biomarker determinations collected from March 2018 to January 2019, from 38 Spanish hospitals, was carried out. Only adenocarcinoma and not otherwise specified histologies were included for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and programmed death ligand-1 (PD-L1) expression. The testing rate and the positivity rate were calculated. Multivariate logistic regression was used to explore the joint relationship between independent explanatory factors and both testing and positivity rates. Two models were adjusted: one with sample type and histology as independent factors, and the other adding the testing rate or the positivity rate of the other biomarkers.Results3226 patient samples were analysed, where EGFR, ALK, ROS1 and PD-L1 information was collected (a total of 12 904 determinations). Overall, 9118 (71.4%) determinations were finally assessed. EGFR (91.4%) and ALK (80.1%) were the mainly tested biomarkers. Positivity rates for EGFR, ALK, ROS1 and PD-L1 were 13.6%, 3.4%, 2.0% and 49.2%, respectively. Multivariate models showed a lower testing rate for ALK in surgical pieces, fine-needle aspiration or other types of samples versus biopsies.ConclusionsDespite the high testing rate in EGFR and ALK in NSCLC, the real-world evidence obtained from the LungPath demonstrates that ROS1 and PD-L1 were not determined in a significant portion of patients. LungPath provides crucial information to improve the coverage in molecular testing in lung cancer, to monitor the positivity rate and the introduction of new biomarker testing in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document